,,ii ,calendar ,no4 #dad #aadth ,,congress #b;d ,session ,s4 #agfg ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,july #ae1 #bjae,mr4 ,isakson 7for himself1 ,mr4 ,casey1 ,mr4 ,roberts1 ,mr4 ,toomey1 ,mr4 ,kirk1 ,mr4 ,donnelly1 and ,mr4 ,cassidy7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,april #e1 #bjaf,reported by ,mr4 ,alexander1 with an amendment,strike out all after the enacting clause and insert the part printed in italic ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act with respect to combination products1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,combination ,product ,regulatory ,fairness ,act of #bjae4 #b4 ,device definition ,section #bja7;h7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba7;h77 is amended-- 7#a7 by redesignating subparagraphs 7#a71 7#b71 and 7#c7 as clauses 7,a71 7,b71 and 7,c71 respectively2 7#b7 by striking 7h7 and inserting 7h77#a72 and 7#c7 by adding at the end the following3 7#b7 7,a7 ,before determining that an article does not meet the definition of a device under this paragraph1 the ,secretary shall provide to the sponsor of the article competent and reliable scientific rationale that-- 7i7 cites any scientific evidence relied upon to support the rationale2 and 7ii7 supports such determination4 7,b7 ,if the ,secretary makes a determination described in clause 7,a7-- 7i7 the sponsor of the article may propose a nonclinical or clinical study1 limited to not more data than necessary to establish the significance1 if any1 of the chemical action in achieving the primary intended purpose of the article2 and 7ii7 the ,secretary and the sponsor of the article shall collaborate in good faith to reach agreement1 within a reasonable time not to exceed #ij days1 on the design of such study4 7,c7 ,the data resulting from a study conducted under clause 7,b7 shall inform the classification of the article4 4 #c4 ,combination products ,section #ejc7;g7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cec7;g77 is amended-- 7#a7 by redesignating paragraphs 7#b7 through 7#e7 as paragraphs 7#f7 through 7#i71 respectively2 7#b7 by striking 7g77#a7 and all that follows through the end of paragraph 7#a7 and inserting the following3 7g7 7#a7 7,a7 ,the ,secretary shall1 in accordance with this subsection1 assign an agency center to regulate products that constitute a combination of a drug1 device1 or biological product 7referred to in this subsection as the lead center74 7,b7 ,the ,secretary shall conduct the premarket review of any combination product1 whenever possible1 under a single application using existing premarket review authorities4 7,c7 ,the ,secretary shall determine the primary mode of action of the combination product4 ,if the ,secretary determines that the primary mode of action is that of-- 7i7 a drug 7other than a biological product71 the agency center charged with premarket review of drugs shall have primary jurisdiction2 7ii7 a device1 the agency center charged with premarket review of devices shall have primary jurisdiction2 or 7iii7 a biological product1 the agency center charged with premarket review of biological products shall have primary jurisdiction4 7,d7 ,in determining the primary mode of action of a combination product1 the ,secretary shall not determine that the primary mode of action is that of a drug or biological product solely because the combination product has any chemical action within or on the human body4 7,e7 ,if the ,secretary disagrees with the conclusions of the sponsor on the primary mode of action of the combination product1 the ,secretary shall provide a competent and reliable scientific rationale to the product sponsor that cites any scientific evidence relied upon to support the decision4 7,f7 ,for purposes of this paragraph-- 7i7 the term primary mode of action means the single mode of action of a combination product that provides the most important therapeutic action of the combination product2 and 7ii7 the term most important therapeutic action means the mode of action expected to make the greatest contribution to the overall intended therapeutic effects of the combination product4 7#b7 7,a7 ,the sponsor of a combination product may submit a combination product review plan 7referred to in this subsection as a ,,cprp7 for the combination product1 and may request a meeting prior to submission of the ,,cprp1 to establish clarity and certainty for the sponsor regarding the standards and requirements applicable to-- 7i7 the review of safety and effectiveness1 or substantial equivalence1 of the combination product2 7ii7 a postmarket modification of the combination product2 or 7iii7 good manufacturing practices for the combination product4 7,b7 ,not later than #fj days after the sponsor of a combination product submits a proposed ,,cprp1 including a revision to a previously proposed or approved ,,cprp1 the ,secretary shall review the ,,cprp and-- 7i7 if the ,secretary determines that the ,,cprp is appropriate to ensure adequate review of the safety and effectiveness1 or substantial equivalence1 of the combination product-- 7,i7 approve the ,,cprp2 and 7,,ii7 issue to the sponsor a response indicating such approval2 or 7ii7 if the ,secretary finds that the ,,cprp does not meet the standard specified in clause 7i7-- 7,i7 decline to approve the ,,cprp2 and 7,,ii7 issue to the sponsor a response indicating that the ,secretary has declined such approval and specifying any deficiencies in the proposed ,,cprp4 7,c7 7i7 ,in the case of a ,,cprp that the ,secretary declines to approve under subparagraph 7,b77ii71 unless the sponsor submitting such ,,cprp determines a meeting is not necessary1 the ,secretary shall1 not later than #cj days after submitting a response under such subparagraph1 meet with such sponsor to discuss the ,,cprp4 7ii7 ,a meeting under clause 7i7 shall-- 7,i7 include any necessary experts from the relevant agency centers2 and 7,,ii7 coordinate the advice of such experts4 7,d7 ,the sponsor or applicant shall provide information necessary for discussion and agreement on the level of evidence necessary to ensure adequate review of the safety and effectiveness1 or substantial equivalence1 of the combination product4 7,e7 ,not later than #cj days after the date on which a meeting is held under subparagraph 7,a77i71 the minutes of such meeting shall be prepared by the sponsor and made available to the ,secretary4 7,f7 ,any agreement that is reached between the ,secretary and a sponsor or applicant through a meeting held under subparagraph 7,a77i7 shall be reduced to writing by the sponsor or applicant1 and1 once approved by the ,secretary1 made part of the administrative record by the ,secretary within #fj days of such meeting4 7,g7 ,an agreement described in subparagraph 7,f7 shall not be changed after approval of the agreement1 except-- 7i7 with the written agreement of the sponsor or applicant2 or 7ii7 pursuant to a decision1 made in accordance with subparagraph 7,h7 by the director of the reviewing division of the lead center1 in consultation with consulting centers and the ,office1 that a substantial scientific issue essential to determining the safety or effectiveness1 or substantial equivalence1 of the combination product has been identified4 7,h7 ,with respect to a decision under subparagraph 7,g77ii71 the ,secretary shall provide notice1 within #b business days of such decision1 to the sponsor of the combination product and an opportunity for a meeting to take place not later than #ad calendar days after issuing such notice1 at which-- 7i7 the director of the reviewing division of the lead center1 staff from the consulting agency centers1 representatives of the ,office1 and the sponsor will be present2 and 7ii7 the director of the reviewing division of the lead center will document the scientific issue involved4 7#c7 ,for purposes of conducting the premarket review of a combination product that contains an approved constituent product described in paragraph 7#d71 the ,secretary may require only that the sponsor of such combination product submit to the ,secretary data or information that-- 7,a7 the ,secretary determines is necessary to assess the specific safety and effectiveness questions and incremental risks posed by the combination product1 using a risk-based approach and taking into account any prior finding of safety and efficacy or substantial equivalence for the approved constituent product2 and 7,b7 is not duplicative of data or information included in an application or other material submitted to the ,secretary in connection with the approved constituent product4 7#d7 ,for purposes of paragraph 7#c71 an approved constituent product is-- 7,a7 a drug constituent part of a combination product being reviewed in a single application under section #eae or #eaj7k71 provided such drug constituent part was previously approved under section #eje and such application complies with subparagraph 7,a7 of paragraph 7#e7 and is subject to subparagraphs 7,d7 and 7,e7 of such paragraph2 7,b7 a device constituent part approved under section #eae that is referenced by the sponsor and which is available for use by the ,secretary under section #ebj7;h77#d72 or 7,c7 any constituent part that was previously approved1 cleared1 or licensed under section #eje1 #eaj7k71 or #eae of this ,act or section #cea of the ,public ,health ,service ,act1 for which the sponsor has a right of reference or which is otherwise available for consideration by the ,secretary under this ,act or the ,public ,health ,service ,act4 7#e7 7,a7 ,if an application is submitted under section #eae or #eaj7k7 for a combination product containing as a constituent part an approved drug-- 7i7 the application shall include the certification or statement required pursuant section #eje7;b77#b72 and 7ii7 the applicant shall provide notice as required pursuant to section #eje7;b77#c74 7,b7 ,for purposes of this paragraph1 the term approved drug means a drug-- 7i7 that was previously approved under section #eje2 7ii7 for which full reports of investigations that have been made to show whether such drug is safe for use and whether such drug is effective in use-- 7,i7 are relied upon by the applicant submitting the application described in subparagraph 7,a72 and 7,,ii7 were not conducted by or for such applicant2 and 7iii7 with respect to which1 the applicant submitting the application described in subparagraph 7,a7 has not obtained a right of reference or use from the person by or for whom the investigations were conducted4 7,c7 ,the following provisions shall apply with respect an application described in subparagraph 7,a73 7i7 ,subparagraphs 7,a71 7,b71 7,c71 and 7,d7 of section #eje7;c77#c74 7ii7 ,clauses 7ii71 7iii71 and 7iv7 of section #eje7;c77#c77;,e74 7iii7 ,paragraphs 7b7 and 7c7 of section #eje;,a4 7iv7 ,section #eje;,e7a74 7v7 ,section #ebg7;a74 7,d7 ,notwithstanding section #ebj7;h77#d77;,a77i71 information contained in an application for premarket approval filed with the ,secretary pursuant to section #eae7;c7 may not be used to approve any application submitted under section #eae or #eaj7k7 for a combination product containing as a constituent part a drug previously approved under section #eje unless-- 7i7 the application includes the certification or statement referenced in subparagraph 7,a72 7ii7 the applicant provides notice as described in subparagraph 7,a72 and 7iii7 the ,secretary's approval of such application is subject to the provisions specified in subparagraph 7,c74 7,e7 ,an application for a combination product described in subparagraph 7,a7 or 7,d7 shall be considered an application submitted under ,section #eje7;b77#b7 solely for purposes of section #bga7;e77#b77;,a7 of the ,patent ,act4 2 7#c7 in paragraph 7#h7 7as redesignated by paragraph 7#a77-- 7,a7 in subparagraph 7,c7-- 7i7 by amending clause 7i7 to read as follows3 7i7 ,in carrying out this subsection1 the ,office shall ensure timely and effective premarket reviews involving more than one agency center by-- 7,i7 overseeing the timeliness and alignment of reviews2 and 7,,ii7 coordinating reviews4 2 7ii7 in clause 7ii71 by inserting and alignment after the timeliness each place it appears2 and 7iii7 by adding at the end the following new clauses3 7iii7 ,the ,office shall ensure that the lead center be the primary point of contact for the sponsor of the product4 ,the ,office shall also coordinate communications to and from any consulting agency center involved in such premarket review4 ,agency communications and commitments1 to the extent consistent with other provisions of law and the requirements of all affected agency centers1 from the lead center shall be binding on all other centers involved in the review4 7iv7 ,the ,office shall1 with respect to the premarket review of a combination product-- 7,i7 ensure that any meeting between the ,food and ,drug ,administration and the sponsor of the product is attended by each agency center involved in the review1 as appropriate2 7,,ii7 require that each consulting agency center has completed its premarket review and provided the results of such review to the lead center within timeframes that allow the lead center to meet the review goals established pursuant to the most recent authorization or reauthorization of parts #b1 #c1 #g1 and #h1 as applicable1 of subchapter ,c of title ,,vii2 and 7,,iii7 ensure that each consulting agency center complies with the guidance described in clause 7vi7 and other relevant regulations1 guidances1 and policies4 7v7 ,not later than #aj days after the receipt by an agency center of an application under section #eje1 #eaj7k71 or #ebj of this ,act1 or under section #cea of the ,public ,health ,service ,act1 for a combination product or an application for investigational use of a combination product under section #eje7;i7 or #ebj7;g71 the agency center shall inform the ,office of such receipt4 7vi7 ,not later than #b years after the date of enactment of the ,combination ,product ,regulatory ,fairness ,act of #bjae1 the ,secretary shall issue final guidance that describes the responsibilities of each agency center regarding its review of combination products1 including each center's role in evaluating evidence development and review under a risk-based approach1 dispute resolution1 labeling1 product usability assessments1 and human factors testing4 ,the ,office shall1 after soliciting public comment1 review and update the guidance at least biannually and specify in such updated guidance the reasons for updates4 2 7,b7 in subparagraph 7,e7-- 7i7 by striking clause 7i7 and inserting the following new clause3 7i7 ,during the review process1 any dispute regarding the substance1 timeliness1 review process1 requirements1 or alignment of the premarket review may be presented to the ,office for resolution and the ,office shall convene the relevant parties and resolve conflicts not later than #ij days after the date on which the ,office receives written notice of such conflicts4 2 and 7ii7 in clause 7ii71 by striking ,during the review process1 any dispute regarding the substance of the premarket review and inserting ,any remaining dispute2 7,c7 in subparagraph 7,f71 in the first sentence-- 7i7 by inserting or which involves determining the safety or efficacy of a component of a combination product after assignment of combination products to agency centers2 and 7ii7 by inserting and with the guidance described in subparagraph 7,c77vi74 before the period at the end2 and 7,d7 in subparagraph 7,g7-- 7i7 in clause 7ii71 by striking and at the end2 7ii7 in clause 7iii71 by striking the period at the end and inserting a semicolon2 and 7iii7 by adding at the end the following new clauses3 7iv7 identifying the percentage of combination products for which a dispute resolution1 with respect to premarket review1 was requested by the combination product's sponsor2 and 7v7 identifying the percentage of meetings between the ,food and ,drug ,administration and the sponsor of a combination product at which all of the centers participating in the review of the combination product were in attendance1 in accordance with subparagraph 7,c77iv77,i74 2 7#d7 in paragraph 7#i7 7as redesignated by paragraph 7#a771 by adding at the end the following3 7,d7 ,the terms premarket review and reviews include all activities of the ,food and ,drug ,administration conducted prior to approval or clearance of an application or notification submitted under section #eje1 #eaj7k71 #eae1 or #ebj of this ,act or under section #cea of the ,public ,health ,service ,act1 including with respect to investigational use of the product4 2 and 7#e7 by adding at the end the following3 7#aj7 ,rule of construction ,nothing in this subsection shall be construed as prohibiting a sponsor1 at the sponsor's discretion1 from submitting separate applications for the constituent parts of a combination product1 unless the ,secretary determines that a single application is necessary to ensure the safety and effectiveness1 or substantial equivalence1 as applicable1 of the combination product4 4 #a4 ,short title ,this ,act may be cited as the ,combination ,product ,regulatory ,fairness ,act of #bjaf4 #b4 ,combination products 7a7 ,in general ,section #ejc7;g7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cec7;g77 is amended-- 7#a7 by striking paragraph 7#c72 7#b7 by redesignating paragraph 7#b7 as paragraph 7#g72 7#c7 by redesignating paragraphs 7#d7 and 7#e7 as paragraphs 7#h7 and 7#i71 respectively2 and 7#d7 by striking 7g77#a7 and all that follows through the end of paragraph 7#a7 and inserting the following3 7g7 7#a7 7,a7 ,the ,secretary shall1 in accordance with this subsection1 assign a primary agency center to regulate products that constitute a combination of a drug1 device1 or biological product4 7,b7 ,the ,secretary shall conduct the premarket review of any combination product under a single application1 whenever appropriate4 7,c7 ,for purposes of this subsection1 the term primary mode of action means the single mode of action of a combination product expected to make the greatest contribution to the overall intended therapeutic effects of the combination product4 7,d7 ,the ,secretary shall determine the primary mode of action of the combination product4 ,if the ,secretary determines that the primary mode of action is that of-- 7i7 a drug 7other than a biological product71 the agency center charged with premarket review of drugs shall have primary jurisdiction2 7ii7 a device1 the agency center charged with premarket review of devices shall have primary jurisdiction2 or 7iii7 a biological product1 the agency center charged with premarket review of biological products shall have primary jurisdiction4 7,e7 ,in determining the primary mode of action of a combination product1 the ,secretary shall not determine that the primary mode of action is that of a drug or biological product solely because the combination product has any chemical action within or on the human body4 7,f7 ,if a sponsor of a combination product disagrees with the determination under subparagraph 7,d7-- 7i7 such sponsor may request1 and the ,secretary shall provide1 a substantive rationale to such sponsor that references scientific evidence provided by the sponsor and any other scientific evidence relied upon by the ,secretary to support such determination2 and 7ii7 7,i7 the sponsor of the combination product may propose one or more studies 7which may be nonclinical1 clinical1 or both7 to establish the relevance1 if any1 of the chemical action in achieving the primary mode of action of such product2 7,,ii7 if the sponsor proposes any such studies1 the ,secretary and the sponsor of such product shall collaborate and seek to reach agreement1 within a reasonable time of such proposal1 not to exceed #ij calendar days1 on the design of such studies2 and 7,,iii7 if an agreement is reached under subclause 7,,ii7 and the sponsor conducts one or more of such studies1 the ,secretary shall consider the data resulting from any such study when reevaluating the determination of the primary mode of action of such product1 and unless and until such reevaluation has occurred and the ,secretary issues a new determination1 the determination of the ,secretary under subparagraph 7,d7 shall remain in effect4 7#b7 7,a7 7i7 ,to establish clarity and certainty for the sponsor1 the sponsor of a combination product may submit a proposed combination product review plan with respect to such combination product1 at any point following the ,secretary's determination of the primary mode of action pursuant to paragraph 7#a74 7ii7 ,such proposed combination product review plan may-- 7,i7 address the standards and requirements for market approval or clearance of the combination product2 7,,ii7 address other issues relevant to such combination product1 such as requirements related to postmarket modification of such combination product and good manufacturing practices applicable to such combination product2 and 7,,iii7 identify elements under subclauses 7,i7 and 7,,ii7 that may be more appropriate for discussion and agreement with the ,secretary at a later date given that scientific or other information is not available1 or agreement is otherwise not feasible regarding such elements1 at the time such plan is submitted4 7,b7 ,after the sponsor of a combination product submits a proposed combination product review plan under subparagraph 7,a71 the ,secretary shall review such plan and1 in a written response to such sponsor-- 7i7 accept such plan in its entirety1 which may include elements to be the subject of discussion and agreement between the sponsor and the ,secretary at a later date1 as described in subparagraph 7,a77ii77,,iii72 7ii7 accept the plan in part1 which may include elements that have not been accepted at the time of the response and are to be the subject of discussion and agreement between the sponsor and the ,secretary at a later date1 as described in subparagraph 7,a77ii77,,iii71 and elements that the ,secretary declines to accept2 or 7iii7 deny such plan in its entirety4 7,c7 ,when reviewing a proposed combination product review plan under subparagraph 7,b71 the ,secretary shall accept such plan1 or elements of such plan1 if the ,secretary determines that the data to be collected is appropriate-- 7i7 for market approval or clearance of the combination product2 or 7ii7 to otherwise meet relevant standards under this ,act1 as applicable4 7,d7 7i7 ,if the ,secretary declines to accept a proposed combination product review plan under subparagraph 7,b77iii71 or elements of such a plan under subparagraph 7,b77ii71 the ,secretary shall1 in the written response to such sponsor-- 7,i7 include a description of the deficiencies of such plan or such elements1 as applicable2 and 7,,ii7 clarify what elements may be suitable for discussion at a later date4 7ii7 ,if the ,secretary declines to accept a proposed combination product review plan under subparagraph 7,b77iii71 or elements of such a plan under subparagraph 7,b77ii71 the sponsor of such plan may request a meeting with the ,secretary4 ,upon the request of the sponsor1 the ,secretary1 including any necessary experts from the relevant agency centers1 shall meet with the sponsor to discuss a proposed combination product review plan or elements of a combination product review plan that the ,secretary has declined to accept1 for the purpose of discussing the information and requirements necessary to make the plan or elements of such plan acceptable4 ,minutes of such meeting shall be made part of the administrative record4 7iii7 ,if the ,secretary declines to accept a proposed combination product review plan under subparagraph 7,b77iii71 or elements of such a plan under subparagraph 7,b77ii71 a sponsor may resubmit a proposed combination product review plan for consideration by the ,secretary under subparagraph 7,a74 7,e7 ,a combination product review plan accepted under subparagraph 7,b77i71 or the elements of a combination product review plan that are accepted under subparagraph 7,b77ii71 shall remain in effect1 except-- 7i7 with the written agreement of the ,secretary and the sponsor or applicant2 or 7ii7 pursuant to a decision1 made in accordance with subparagraph 7,f7 by the director of the reviewing division of the primary agency center1 or a person more senior than such director1 in consultation with consulting centers and the ,office1 that an important1 materially relevant scientific issue essential to determining the safety or effectiveness1 or substantial equivalence1 as applicable1 of the combination product has been identified since a combination product review plan or elements of a combination product review plan were accepted1 as applicable4 7,f7 ,if the ,secretary makes a decision under subparagraph 7,e77ii71 the ,secretary shall provide notice1 within a reasonable time after such decision1 to the sponsor of the combination product subject to such decision and provide an opportunity for a meeting with the ,secretary1 to take place within a reasonable time after issuing such notice1 at which-- 7i7 the director of the reviewing division of the primary agency center1 or a person more senior than such director1 staff from the consulting centers1 representatives of the ,office1 and the sponsor shall be represented2 and 7ii7 the director of the reviewing division of the primary agency center1 or a person more senior than the director1 shall describe the important1 materially relevant issue involved to such sponsor4 7#c7 ,for purposes of conducting the premarket review of a combination product that contains an approved constituent part described in paragraph 7#d71 the ,secretary may require that the sponsor of such combination product submit to the ,secretary only data or information that the ,secretary determines is necessary to assess the safety and effectiveness of the combination product1 including any incremental risks and benefits posed by such combination product1 using a risk-based approach and taking into account any prior finding of safety and effectiveness or substantial equivalence for the approved constituent part relied upon by the applicant in accordance with paragraph 7#e74 7#d7 ,for purposes of paragraph 7#c71 an approved constituent part is-- 7,a7 a drug constituent part of a combination product being reviewed in a single application or request under section #eae1 #eaj7k71 or #eac7;f77#b7 7submitted in accordance with paragraph 7#e771 that is an approved drug1 provided such application or request complies with paragraph 7#e72 7,b7 a device constituent part approved under section #eae that is referenced by the sponsor and that is available for use by the ,secretary under section #ebj7;h77#d72 or 7,c7 any constituent part that was previously approved1 cleared1 or classified under section #eje1 #eaj7k71 #eac7;f77#b71 or #eae of this ,act for which the sponsor has a right of reference or any constituent part that is a nonprescription drug1 as defined in section #gfj7;a77#b74 7#e7 7,a7 ,if an application is submitted under section #eae1 #eaj7k71 or a request is submitted under section #eac7;f77#b71 consistent with any determination made under paragraph 7#a77;,d71 for a combination product containing as a constituent part an approved drug-- 7i7 the application or request shall include the certification or statement described in section #eje7;b77#b72 and 7ii7 the applicant or requester shall provide notice as described in section #eje7;b77#c74 7,b7 ,for purposes of this paragraph and paragraph 7#d71 the term approved drug means an active ingredient-- 7i7 that was in an application previously approved under section #eje7;c72 7ii7 where such application is relied upon by the applicant submitting the application or request described in subparagraph 7,a72 7iii7 for which full reports of investigations that have been made to show whether such drug is safe for use and whether such drug is effective in use were not conducted by or for the applicant submitting the application or request described in subparagraph 7,a72 and 7iv7 for which the applicant submitting the application or request described in subparagraph 7,a7 has not obtained a right of reference or use from the person by or for whom the investigations described in clause 7iii7 were conducted4 7,c7 ,the following provisions shall apply with respect to an application or request described in subparagraph 7,a7 to the same extent and in the same manner as if such application or request were an application described in section #eje7;b77#b7 that referenced the approved drug3 7i7 ,subparagraphs 7,a71 7,b71 7,c71 and 7,d7 of section #eje7;c77#c74 7ii7 ,clauses 7ii71 7iii71 and 7iv7 of section #eje7;c77#c77;,e74 7iii7 ,subsections 7b7 and 7c7 of section #eje;,a4 7iv7 ,section #eje;,e7a74 7v7 ,section #ebg7;a74 7,d7 ,notwithstanding any other provision of this subsection1 an application or request for classification for a combination product described in subparagraph 7,a7 shall be considered an application submitted under section #eje7;b77#b7 for purposes of section #bga7;e77#b77;,a7 of title #ce1 ,united ,states ,code4 7#f7 ,nothing in this subsection shall be construed as prohibiting a sponsor from submitting separate applications for the constituent parts of a combination product1 unless the ,secretary determines that a single application is necessary4 2 7#e7 in paragraph 7#h7 7as redesignated by paragraph 7#c77-- 7,a7 in subparagraph 7,c7-- 7i7 by amending clause 7i7 to read as follows3 7i7 ,in carrying out this subsection1 the ,office shall help to ensure timely and effective premarket review that involves more than one agency center by coordinating such reviews1 overseeing the timeliness of such reviews1 and overseeing the alignment of feedback regarding such reviews4 2 7ii7 in clause 7ii71 by inserting and alignment after the timeliness each place it appears2 and 7iii7 by adding at the end the following new clauses3 7iii7 ,the ,office shall ensure that1 with respect to a combination product1 a designated person or persons in the primary agency center be the primary point or points of contact for the sponsor of such combination product4 ,the ,office shall also coordinate communications to and from any consulting center involved in such premarket review1 if requested by such primary agency center or any such consulting center4 ,agency communications and commitments1 to the extent consistent with other provisions of law and the requirements of all affected agency centers1 from the primary agency center shall be considered as communication from the ,food and ,drug ,administration on behalf of all agency centers involved in the review4 7iv7 ,the ,office shall1 with respect to the premarket review of a combination product-- 7,i7 ensure that any meeting between the ,food and ,drug ,administration and the sponsor of such product is attended by each agency center involved in the review1 as appropriate2 7,,ii7 ensure that each consulting agency center has completed its premarket review and provided the results of such review to the primary agency center in a timely manner2 and 7,,iii7 ensure that each consulting center follows the guidance described in clause 7vi7 and advises1 as appropriate1 on other relevant regulations1 guidances1 and policies4 7v7 ,in seeking agency action with respect to a combination product1 the sponsor of such product-- 7,i7 shall identify the product as a combination product2 and 7,,ii7 may request in writing the participation of representatives of the ,office in meetings related to such combination product1 or to have the ,office otherwise engage on such regulatory matters concerning the combination product4 7vi7 ,not later than #d years after the date of enactment of the ,combination ,product ,regulatory ,fairness ,act of #bjaf1 and after a public comment period of not less than #fj calendar days1 the ,secretary shall issue a final guidance that describes-- 7,i7 the responsibilities of each agency center regarding its review of combination products1 including each center's role in evaluating evidence development and review under a risk-based approach1 dispute resolution1 labeling1 product usability assessments1 and human factors testing2 7,,ii7 the structured process for managing pre-submission interactions with sponsors developing combination products2 7,,iii7 the best practices for ensuring that the feedback in such pre-submission interactions represents the ,agency's best advice based on the information provided during such pre-submission interactions2 7,,iv7 the best practices regarding submissions by sponsors1 and review by the ,secretary1 of combination product review plans under paragraph 7#b71 including the appropriate timing for discussion and agreement of such plans1 and the various elements of such plans1 based on scientific and technical understanding during product development2 7,v7 the ,secretary's processes for ensuring input from experts from each relevant agency center in such pre-submission interactions with sponsors developing combination products and in fulfilling the requirements of this subsection2 7,,vi7 the timelines associated with responding to1 and holding meetings regarding1 combination product review plans under paragraph 7#b72 and 7,,vii7 disputes appropriate for presentation to the ,office as described in subparagraph 7,e77i74 4 7,b7 in subparagraph 7,e7-- 7i7 by striking clause 7i7 and inserting the following new clause3 7i7 ,during the review process1 disputes between different agency centers regarding the substance1 timeliness1 review process1 requirements1 or alignment of the premarket review with respect to a combination product1 including conflicting feedback1 responses1 and decisions from such agency centers1 may be presented to the ,office by the sponsor of such combination product for resolution and the ,office shall convene the relevant parties and seek to resolve such conflicts4 2 and 7ii7 in clause 7ii71 by striking ,during the review process1 any dispute regarding the substance of the premarket review and inserting ,any dispute remaining after the process under clause 7i7 is completed2 7,c7 in subparagraph 7,f71 in the first sentence-- 7i7 by inserting or that involves determining the safety or efficacy1 reasonable assurance of safety and efficacy1 or substantial equivalence of a component of a combination product after assignment of combination products to agency centers2 and 7ii7 by inserting and with the guidance described in subparagraph 7,c77vi7 before the period at the end2 and 7,d7 in subparagraph 7,g7-- 7i7 in clause 7ii71 by striking and at the end2 7ii7 in clause 7iii71 by striking the period at the end and inserting a semicolon2 and 7iii7 by adding at the end the following new clauses3 7iv7 identifying the percentage of combination products for which a dispute resolution1 with respect to premarket review1 was requested by the combination product's sponsor2 7v7 stating the average1 median1 and range of response times to combination product review plans under paragraph 7#b72 7vi7 identifying the percentage of meetings between the ,food and ,drug ,administration and the sponsor of a combination product at which all of the agency centers participating in the review of the combination product were in attendance1 in accordance with subparagraph 7,c77iv77,i72 and 7vii7 for the report submitted in #bjag1 and in a report at least once every #e years thereafter1 regarding any recommendations to streamline premarket review of combination products4 2 and 7#f7 in paragraph 7#i7 7as redesignated by paragraph 7#c77-- 7,a7 in subparagraph 7,c7-- 7i7 in clause 7ii71 by striking and2 7ii7 in clause 7iii71 by striking the period and inserting 1 and2 and 7iii7 by adding at the end the following3 7iv7 de novo classification under section #eac7;a77#a74 2 and 7,b7 by adding at the end the following3 7,d7 ,the terms premarket review and reviews include all activities of the ,food and ,drug ,administration conducted prior to approval or clearance of an application1 notification1 or request for classification submitted under section #eje1 #eaj7k71 #eac7;f77#b71 #eae1 or #ebj of this ,act or under section #cea of the ,public ,health ,service ,act1 including with respect to investigational use of the product4 4 7b7 ,information for approval of combination products ,section #ebj7;h77#d7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;j7 is amended-- 7#a7 in subparagraph 7,a71 by striking ,any information and inserting 8,subject to subparagraph 7,c71 any information02 and 7#b7 by adding at the end the following new subparagraph3 7,c7 ,no information contained in an application for premarket approval filed with the ,secretary pursuant to section #eae7;c7 may be used to approve or clear any application submitted under section #eae or #eaj7k7 or to classify a product under section #eac7;f77#b7 for a combination product containing as a constituent part an 8approved drug0 as defined in section #ejc7;g77#e77;,b7 unless-- 7i7 the application includes the certification or statement referenced in section #ejc7;g77#e77;,a72 7ii7 the applicant provides notice as described in ,section #ejc7;g77#e77;,a72 and 7iii7 the ,secretary's approval of such application is subject to the provisions in section #ejc7;g77#e77;,c74 4 7c7 ,variations ,from ,,cgmp ,streamlined ,approach ,not later than #ah months after the date of enactment of this ,act1 the ,secretary shall identify types of combination products that the ,secretary proposes may adopt good manufacturing practices that vary from the requirements set forth in section #d4d of title #ba1 ,code of ,federal ,regulations 7or any successor regulations74 ,the ,secretary shall identify such types1 and identify variations from such requirements1 in a proposed list published in the ,federal ,register4 ,after a public comment period regarding the appropriate good manufacturing practices for such types1 the ,secretary shall publish a final list in the ,federal ,register1 notwithstanding section #eec of title #e1 ,united ,states ,code4 ,the ,secretary shall evaluate such types and such appropriate variations using a risk-based approach4 ,the ,secretary shall periodically review such types on such final list1 including whether additional types of combination products are appropriate for such final list4 ,april #e1 #bjaf,reported with an amendment